PHAT

PHATHOM PHARMACEUTICALS, INC.

PHAT · CIK 1783183 · Annual (10-K) · Last 7 years

Financial Trends

Revenue$175M
20192025
Net Income−$221M
20192025
Operating CF−$167M
20192025
Free Cash Flow−$167M
20192025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Revenue$0.2B$0.1B$0.0B————
Cost of Revenue$0.0B$0.0B$0.0B————
Gross Profit$0.2B$0.0B$0.0B————
R&D Expense$0.0B$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B
SG&A Expense$0.3B$0.3B$0.1B————
Operating Income$-0.2B$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B
Net Income$-0.2B$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-3.03$-5.29$-3.93$-5.05———
EPS (Diluted)$-3.03$-5.29$-3.93$-5.05———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Total Assets$0.3B$0.4B$0.4B$0.2B$0.2B$0.3B$0.3B
Current Assets$0.2B$0.4B$0.4B$0.2B$0.2B$0.3B$0.3B
Cash & Equivalents$0.1B$0.3B$0.4B$0.2B$0.2B$0.3B$0.2B
Total Liabilities$0.7B$0.6B$0.5B$0.2B$0.1B$0.1B$0.0B
Current Liabilities$0.1B$0.1B$0.0B$0.0B$0.0B$0.1B$0.0B
Stockholders' Equity$-0.4B$-0.3B$-0.1B$-0.1B$0.1B$0.2B$0.2B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Operating Cash Flow$-0.2B$-0.3B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$0.2B$0.4B$0.1B$0.0B$0.1B$0.3B
← Companies